Elanco Animal Health Incorporated (ELAN)
NYSE: ELAN · Real-Time Price · USD
18.43
+0.96 (5.50%)
Sep 5, 2025, 4:00 PM - Market closed
Elanco Animal Health Revenue
Elanco Animal Health had revenue of $1.24B in the quarter ending June 30, 2025, with 4.81% growth. This brings the company's revenue in the last twelve months to $4.48B, down -0.18% year-over-year. In the year 2024, Elanco Animal Health had annual revenue of $4.44B with 0.50% growth.
Revenue (ttm)
$4.48B
Revenue Growth
-0.18%
P/S Ratio
2.03
Revenue / Employee
$474,497
Employees
9,450
Market Cap
9.16B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 4.44B | 22.00M | 0.50% |
| Dec 31, 2023 | 4.42B | 6.00M | 0.14% |
| Dec 31, 2022 | 4.41B | -353.00M | -7.41% |
| Dec 31, 2021 | 4.76B | 1.49B | 45.64% |
| Dec 31, 2020 | 3.27B | 200.00M | 6.51% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
ELAN News
- 10 days ago - Splenda® Joins Elanco and HATCH to Support 'Nutrition Secure Indianapolis' to Strengthen Family Health Through Nutrition and Education - PRNewsWire
- 11 days ago - Elanco Animal Health Set to Join S&P MidCap 400; Sarepta Therapeutics to Join S&P SmallCap 600 - PRNewsWire
- 11 days ago - Elanco to Participate in Morgan Stanley 23rd Annual Global Healthcare Conference - PRNewsWire
- 4 weeks ago - Elanco Animal Health Incorporated (ELAN) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Elanco Animal Health Q2: Rising Innovation Revenue, Initiate At Buy - Seeking Alpha
- 4 weeks ago - Elanco Animal Health Soars Past 52-Week High On Strong Sales, Raised Annual Outlook - Benzinga
- 4 weeks ago - Elanco Animal Health Reports Second Quarter 2025 Results - PRNewsWire
- 6 weeks ago - Elanco Secures Approval of Zenrelia™ (ilunocitinib) in the European Union (EU), Launching Innovative Canine Dermatology Treatment for Itchy Dogs - PRNewsWire